Ovid Therapeutics dosed healthy volunteers with OV329 in Phase 1 trial

Ovid Therapeutics dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study. The Company is conducting the study to evaluate the safety and target engagement associated with single and repeated doses of OV329. "Inhibiting the GABA-aminotransferase enzyme is a validated mechanism for reducing seizures," said Dr. Claude Nicaise, Head of Research & Development at Ovid. "We believe OV329 is an improved, potent GABA-AT inhibitor that may confer robust seizure reduction, an improved safety profile, and preferred dosing relative to the current medicine in the class. We thank the epilepsy community and individuals participating in this Phase 1 study. Results will inform our development plans, and hopefully, enable us to rapidly advance into trials with people experiencing treatment-resistant seizures."